Drug development and PET-diagnostics for Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current Medicinal Chemistry

• Publication date

  2005-06-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/0929867054367130PMID 16022665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Role of acyl-coenzyme A

  2007cited by this paper
• List of Drugs in Development for Neurodegenerative Diseases

  2004cited by this paper
• Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR.

  2004cited by this paper
• The presenilin C‐terminus is required for ER‐retention, nicastrin‐binding and γ‐secretase activity

  2004cited by this paper
• Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases.

  2004cited by this paper
• Doctors seek lost data on Alzheimer's vaccine

  2004cited by this paper
• Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)

  2004cited by this paper
• Problems and Solutions in the Genetic Analysis of Late-Onset Alzheimer’s Disease

  2004cited by this paper
• Identification of distinct gamma-secretase complexes with different APH-1 variants.

  2004cited by this paper
• Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease.

  2004cited by this paper
• P3 cap modified Phe*-Ala series BACE inhibitors.

  2004cited by this paper
• Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis.

  2004cited by this paper
• KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.

  2004cited by this paper
• Stereochemical analysis of (hydroxyethyl)urea peptidomimetic inhibitors of gamma-secretase.

  2004cited by this paper
• APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease.

  2004cited by this paper
• Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase.

  2004cited by this paper
• Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site

  2004cited by this paper
• Pathways towards and away from Alzheimer's disease

  2004cited by this paper
• AD2000: donepezil in Alzheimer's disease.

  2004cited by this paper
• Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).

  2004cited by this paper
• Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase.

  2004cited by this paper
• Alzheimer's disease.

  2004cited by this paper
• Clioquinol Mediates Copper Uptake and Counteracts Copper Efflux Activities of the Amyloid Precursor Protein of Alzheimer's Disease*

  2004cited by this paper
• γ-Secretase: proteasome of the membrane?

  2004cited by this paper
• Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

  2004cited by this paper
• Identification of a New Presenilin-dependent ζ-Cleavage Site within the Transmembrane Domain of Amyloid Precursor Protein*♦

  2004cited by this paper
• Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme.

  2004cited by this paper
• Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.

  2004cited by this paper
• Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.

  2004cited by this paper
• Efficacy of flupirtine on cognitive function in patients with CJD

  2004cited by this paper
• Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.

  2004cited by this paper
• Modeling the binding affinities of beta-secretase inhibitors: application to subsite specificity.

  2004cited by this paper
• Rational design and synthesis of selective BACE-1 inhibitors.

  2004cited by this paper
• Modeling the protonation states of the catalytic aspartates in beta-secretase.

  2004cited by this paper
• Parallel synthesis of DAPT derivatives and their gamma-secretase-inhibitory activity.

  2004cited by this paper
• Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors.

  2004cited by this paper
• Structure-based design of estrogen receptor-beta selective ligands.

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Apo and inhibitor complex structures of BACE (beta-secretase).

  2004cited by this paper
• Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain

  2004cited by this paper
• GSK3 inhibitors: development and therapeutic potential

  2004cited by this paper
• Histochemical analysis of senile plaque amyloid and amyloid angiopathy

  2004cited by this paper
• Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease.

  2004cited by this paper
• Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

  2004cited by this paper
• No replication of the association between the Nicastrin gene and familial early-onset Alzheimer's disease.

  2003cited by this paper
• Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

  2003cited by this paper
• NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design.

  2003cited by this paper
• Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies.

  2003cited by this paper
• Synthesis and gamma-secretase activity of APP substrate-based hydroxyethylene dipeptide isosteres.

  2003cited by this paper
• Easy access to novel substituted 6-aminoimidazo[1,2-a]pyridines using palladium- and copper-catalyzed aminations.

  2003cited by this paper
• Alzheimer disease's double-edged vaccine

  2003cited by this paper
• Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.

  2003cited by this paper
• GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

  2003cited by this paper
• Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain*

  2003cited by this paper
• Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.

  2003cited by this paper
• Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement.

  2003cited by this paper
• Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Divergent roles of GSK3 and CDK5 in APP processing.

  2003cited by this paper
• The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component

  2003cited by this paper
• Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho.

  2003cited by this paper
• Ipso- or cine-substitutions of 6-haloimidazo[1,2-a]pyridine derivatives with different azoles depending on the reaction conditions.

  2003cited by this paper
• Calculation of the binding affinity of beta-secretase inhibitors using the linear interaction energy method.

  2003cited by this paper
• A new series of potent benzodiazepine gamma-secretase inhibitors.

  2003cited by this paper
• Partial purification and characterization of gamma-secretase from post-mortem human brain.

  2003cited by this paper
• KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides.

  2003cited by this paper
• Aspartic Proteases Involved in Alzheimer's Disease

  2003cited by this paper
• Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

  2003cited by this paper
• Reconstitution of gamma-secretase activity.

  2003cited by this paper
• Nicastrin gene in familial and sporadic Alzheimer's disease.

  2003cited by this paper
• Design of substrate-based inhibitors of human beta-secretase.

  2002cited by this paper
• Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic Protease

  2002cited by this paper
• The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity

  2002cited by this paper
• Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100.

  2002cited by this paper
• Presenilin-dependent gamma-secretase activity modulates neurite outgrowth.

  2002cited by this paper
• 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.

  2002cited by this paper
• The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease.

  2002cited by this paper
• The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells.

  2002cited by this paper
• '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease.

  2002cited by this paper
• The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling.

  2002cited by this paper
• Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

  2002cited by this paper
• Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?

  2002cited by this paper
• Memapsin 2 (beta-secretase) as a therapeutic target.

  2002cited by this paper
• A series of C-terminal amino alcohol dipeptide A beta inhibitors.

  2002cited by this paper
• Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

  2002cited by this paper
• Genotype and phenotype in Alzheimer's disease

  2002cited by this paper
• Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity.

  2002cited by this paper
• Endoproteolysis of presenilin in vitro: inhibition by gamma-secretase inhibitors.

  2002cited by this paper
• Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

  2002cited by this paper
• Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3.

  2002cited by this paper
• Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate.

  2002cited by this paper
• Direct visualization of the gamma secretase‐generated carboxyl‐terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus

  2002cited by this paper
• Substrate and Inhibitor Profile of BACE (β-Secretase) and Comparison with Other Mammalian Aspartic Proteases*

  2002cited by this paper
• Dancing in the dark?

  2001cited by this paper
• Transgenic mouse models of Alzheimer's disease.

  2001cited by this paper
• Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

  2001cited by this paper

• Environmental benign catalyst developed by fruit waste for synthesis of β-amino alcohol with the optimum combination through statistical analysis

  2025cites this paper
• The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimer’s Disease

  2022cites this paper
• Receptors for Advanced Glycation End Products (RAGE): Promising Targets Aiming at the Treatment of Neurodegenerative Conditions

  2022cites this paper
• Radiosynthesis of a carbon-11 labeled tetrahydrobenzisoxazole derivative as a new PET probe for γ-secretase imaging in Alzheimer's disease.

  2020cites this paper
• Experimental and Computational Studies of Microwave-Assisted, Facile Ring Opening of Epoxide with Less Reactive Aromatic Amines in Nitromethane

  2020cites this paper
• Tetrahydroquinoline-Isoxazole/Isoxazoline Hybrid Compounds as Potential Cholinesterases Inhibitors: Synthesis, Enzyme Inhibition Assays, and Molecular Modeling Studies

  2019cites this paper
• Potential Role of Curcumin and Its Derivatives Against Alzheimer Disease

  2019cites this paper
• Molecular Docking, Synthesis, in Silico and in vitro Screening of Substituted Aryl Ureido Analogues as BACE1 Inhibitors to target Alzheimer’s Disease

  2018cites this paper
• Flavones from Heavenly Blue as modulators of Alzheimer’s amyloid-beta peptide (Aβ) production

  2018cites this paper
• Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals.

  2017cites this paper
• QSAR, docking, and Molecular dynamic studies on the polyphenolic as inhibitors of β-amyloid aggregation

  2016cites this paper
• Insulin can induce the expression of a memory-related synaptic protein through facilitating AMPA receptor endocytosis in rat cortical neurons

  2014cites this paper
• Design, synthesis, in silico and in vitro screening of 1,2,4-thiadiazole analogues as non-peptide inhibitors of beta-secretase.

  2014cites this paper
• Click chemistry based synthesis of dopamine D4 selective receptor ligands for the selection of potential PET tracers.

  2013cites this paper
• Subtype-selective dopamine receptor radioligands for PET imaging: current status and recent developments.

  2012cites this paper
• Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.

  2011cites this paper
• Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.

  2010cites this paper
• fMRI in Psychiatric Disorders

  2009cites this paper
• Functional neuroimaging of cognition.

  2008cites this paper
• Strategies for molecular imaging dementia and neurodegenerative diseases

  2008cites this paper
• Curcumin‐Derived Pyrazoles and Isoxazoles: Swiss Army Knives or Blunt Tools for Alzheimer's Disease?

  2008cites this paper
• Molecular neuroimaging: from conventional to emerging techniques.

  2007cites this paper
• Curcumin Derivatives Inhibit or Modulate Beta-Amyloid Precursor Protein Metabolism

  2007cites this paper
• N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase.

  2007cites this paper
• Conversion of the LXR-agonist TO-901317--from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor.

  2007cites this paper
• New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques.

  2007cites this paper
• Ensemble‐Docking Approach on BACE‐1: Pharmacophore Perception and Guidelines for Drug Design

  2007cites this paper
• A Soluble Amyloid Fibril Segment to Study Aggregate Formation

  2007cites this paper
• Radioligand development for PET imaging of beta-amyloid (Abeta)--current status.

  2007cites this paper
• N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated γ-secretase

  2007cites this paper
• Norstatines from Aldehydes by Sequential Organocatalytic α-Amination and Passerini Reaction

  2006cites this paper
• Modulators and Inhibitors of γ- and β-Secretases

  2006cites this paper
• (S)‐4‐[2‐(3‐Cyano­benzamido)‐3‐hydroxy­prop­yl]phenyl 3‐cyano­benzoate

  2006cites this paper
• Modulators and inhibitors of gamma- and beta-secretases.

  2006cites this paper
• The role of MRI and PET/SPECT in Alzheimer's disease.

  2006cites this paper
• Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation.

  2006cites this paper
• Synthesis of tetramic and tetronic acids as beta-secretase inhibitors.

  2006cites this paper